REG-Bioventix Plc: Trading Update and Notice of Results <Origin Href="QuoteRef">BVXP.L</Origin>

BioventixAnnouncement

04/09/2015 07:00

Bioventix plc                                 
                        ("Bioventix" or the "Company")                         

                     Trading update and notice of results                      

Bioventix plc (BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces a trading update following the year ended 30
June 2015.

As highlighted in the interim results, the core business remains robust and the
board is pleased to report that revenues for the year are expected to be in
excess of £4.2m (2014:£3.5m).  Given the relatively modest and fixed cost base,
profits before tax will be significantly ahead of market expectations.

The Company expects to announce its preliminary results for the year ended 30
June 2015 on 5 October 2015.

For further information please contact:

Bioventix plc                                            Tel: 01252 728 001         
Peter Harrison              Chief Executive Officer                                 
                                                                                    
finnCap Ltd                                              Tel: 020 7220 0500         
Geoff Nash/Simon Hicks      Corporate Finance                                       
Steve Norcross              Corporate Broking                                       

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



END



Copyright © 2015 PR Newswire Association, LLC. All Rights Reserved